chevron_leftBack
As of 24 April 2025, Apontis Pharma AG has a market cap of $108.56M USD, ranking #20284 globally and #258 in Germany. It ranks #2021 in the Healthcare sector, and #457 in the Drug Manufacturers - Specialty & Generic industry.
Key Stats
Market Cap
$108.56MUSD
95.8M EUR
Enterprise Value
$91.05MUSD
80.34M EUR
Revenue (TTM)
$54.93MUSD
48.47M EUR
EBITDA (TTM)
$3.89MUSD
3.43M EUR
Net Income (TTM)
$853.98KUSD
753.57K EUR
EBITDA Margin
7.1%
Profit Margin
1.6%
PE Ratio
127.1
Company Profile
Country (HQ)
Sector
Healthcare
CEO
Bruno Wohlschlegel
open_in_new
Employees
137
Founded
1946
Website
apontis-pharma.de
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -3% | 2.7% | 2.2% | 11% | 20% | 43% |
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
APPH
Apontis Pharma AG Bearer Shares
ISIN: DE000A3CMGM5
Shares Out.:
Shares Outstanding:
8.33M1
Shares Float:
5.165M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
11.15 EUR | |
|
APPH
Apontis Pharma AG Bearer Shares
ISIN: DE000A3CMGM5
|
10.95 EUR |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Apontis Pharma AG
Apontis Pharma AG engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany. It offers single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, hyperlipidemia, and secondary prophylaxis, as well as respiratory diseases and diabetes. The company was founded in 1946 and is based in Monheim am Rhein, Germany. As of November 21, 2024, Apontis Pharma AG operates as a subsidiary of Zentiva AG.
